Etidocaine is marketed under the name Duranest. It is an injectable local anesthetic during surgery, labor, and delivery. Etidocaine has a long duration of activity, but has the main disadvantage of increased bleeding during oral surgery.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Hyaluronidase (ovine) | Hyaluronidase (ovine) can cause an increase in the absorption of Etidocaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Hyaluronidase (human recombinant) | Hyaluronidase (human recombinant) can cause an increase in the absorption of Etidocaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Hyaluronidase | Hyaluronidase can cause an increase in the absorption of Etidocaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Technetium Tc-99m tilmanocept | Etidocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent. |
| Chloroprocaine | The risk or severity of adverse effects can be increased when Etidocaine is combined with Chloroprocaine. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Etidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Ropivacaine is combined with Etidocaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Etidocaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Cinchocaine is combined with Etidocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Dyclonine is combined with Etidocaine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Procaine is combined with Etidocaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Prilocaine is combined with Etidocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Etidocaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Meloxicam is combined with Etidocaine. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Oxybuprocaine is combined with Etidocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Cocaine is combined with Etidocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Mepivacaine is combined with Etidocaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Levobupivacaine is combined with Etidocaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Diphenhydramine is combined with Etidocaine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Benzocaine is combined with Etidocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Phenol is combined with Etidocaine. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Tetrodotoxin is combined with Etidocaine. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Benzyl alcohol is combined with Etidocaine. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Capsaicin is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Etidocaine is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Etidocaine is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Etidocaine is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Etidocaine is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Etidocaine is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Etidocaine is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Etidocaine is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Etidocaine is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Etidocaine is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Etidocaine is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Etidocaine is combined with Quinisocaine. |
| Cetuximab | The risk or severity of methemoglobinemia can be increased when Cetuximab is combined with Etidocaine. |
| Denileukin diftitox | The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Etidocaine. |
| Leuprolide | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Etidocaine. |
| Peginterferon alfa-2a | The risk or severity of methemoglobinemia can be increased when Peginterferon alfa-2a is combined with Etidocaine. |
| Goserelin | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Etidocaine. |
| Asparaginase Escherichia coli | The risk or severity of methemoglobinemia can be increased when Asparaginase Escherichia coli is combined with Etidocaine. |
| Interferon alfa-2a | The risk or severity of methemoglobinemia can be increased when Interferon alfa-2a is combined with Etidocaine. |
| Aldesleukin | The risk or severity of methemoglobinemia can be increased when Aldesleukin is combined with Etidocaine. |
| Gemtuzumab ozogamicin | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Etidocaine. |
| Pegaspargase | The risk or severity of methemoglobinemia can be increased when Pegaspargase is combined with Etidocaine. |
| Trastuzumab | The risk or severity of methemoglobinemia can be increased when Trastuzumab is combined with Etidocaine. |
| Rituximab | The risk or severity of methemoglobinemia can be increased when Rituximab is combined with Etidocaine. |
| Tositumomab | The risk or severity of methemoglobinemia can be increased when Tositumomab is combined with Etidocaine. |
| Alemtuzumab | The risk or severity of methemoglobinemia can be increased when Alemtuzumab is combined with Etidocaine. |
| Octreotide | The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Etidocaine. |
| Interferon alfa-2b | The risk or severity of methemoglobinemia can be increased when Interferon alfa-2b is combined with Etidocaine. |
| Bevacizumab | The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Etidocaine. |
| Masoprocol | The risk or severity of methemoglobinemia can be increased when Masoprocol is combined with Etidocaine. |
| Bortezomib | The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Etidocaine. |
| Pipobroman | The risk or severity of methemoglobinemia can be increased when Pipobroman is combined with Etidocaine. |
| Cladribine | The risk or severity of methemoglobinemia can be increased when Cladribine is combined with Etidocaine. |
| Cabergoline | The risk or severity of methemoglobinemia can be increased when Cabergoline is combined with Etidocaine. |
| Anagrelide | The risk or severity of methemoglobinemia can be increased when Anagrelide is combined with Etidocaine. |
| Carmustine | The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Etidocaine. |
| Chlorotrianisene | The risk or severity of methemoglobinemia can be increased when Chlorotrianisene is combined with Etidocaine. |
| Amsacrine | The risk or severity of methemoglobinemia can be increased when Amsacrine is combined with Etidocaine. |
| Pamidronic acid | The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Etidocaine. |
| Bleomycin | The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Etidocaine. |
| Chlorambucil | The risk or severity of methemoglobinemia can be increased when Chlorambucil is combined with Etidocaine. |
| Raltitrexed | The risk or severity of methemoglobinemia can be increased when Raltitrexed is combined with Etidocaine. |
| Mitomycin | The risk or severity of methemoglobinemia can be increased when Mitomycin is combined with Etidocaine. |
| Bexarotene | The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Etidocaine. |
| Vindesine | The risk or severity of methemoglobinemia can be increased when Vindesine is combined with Etidocaine. |
| Valproic acid | The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Etidocaine. |
| Gefitinib | The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Etidocaine. |
| Floxuridine | The risk or severity of methemoglobinemia can be increased when Floxuridine is combined with Etidocaine. |
| Megestrol acetate | The risk or severity of methemoglobinemia can be increased when Megestrol acetate is combined with Etidocaine. |
| Tioguanine | The risk or severity of methemoglobinemia can be increased when Tioguanine is combined with Etidocaine. |
| Aminoglutethimide | The risk or severity of methemoglobinemia can be increased when Aminoglutethimide is combined with Etidocaine. |
| Vinorelbine | The risk or severity of methemoglobinemia can be increased when Vinorelbine is combined with Etidocaine. |
| Valrubicin | The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Etidocaine. |
| Sorafenib | The risk or severity of methemoglobinemia can be increased when Sorafenib is combined with Etidocaine. |
| Streptozocin | The risk or severity of methemoglobinemia can be increased when Streptozocin is combined with Etidocaine. |
| Trifluridine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Etidocaine. |
| Gemcitabine | The risk or severity of methemoglobinemia can be increased when Gemcitabine is combined with Etidocaine. |
| Teniposide | The risk or severity of methemoglobinemia can be increased when Teniposide is combined with Etidocaine. |
| Epirubicin | The risk or severity of methemoglobinemia can be increased when Epirubicin is combined with Etidocaine. |
| Lenalidomide | The risk or severity of methemoglobinemia can be increased when Lenalidomide is combined with Etidocaine. |
| Altretamine | The risk or severity of methemoglobinemia can be increased when Altretamine is combined with Etidocaine. |
| Flutamide | The risk or severity of methemoglobinemia can be increased when Flutamide is combined with Etidocaine. |
| Cisplatin | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Etidocaine. |
| Alitretinoin | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Etidocaine. |
| Oxaliplatin | The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Etidocaine. |
| Erlotinib | The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Etidocaine. |
| Cyclophosphamide | The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Etidocaine. |
| Toremifene | The risk or severity of methemoglobinemia can be increased when Toremifene is combined with Etidocaine. |
| Vincristine | The risk or severity of methemoglobinemia can be increased when Vincristine is combined with Etidocaine. |
| Fluorouracil | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Etidocaine. |
| Pentostatin | The risk or severity of methemoglobinemia can be increased when Pentostatin is combined with Etidocaine. |
| Methotrexate | The risk or severity of methemoglobinemia can be increased when Methotrexate is combined with Etidocaine. |
| Vinblastine | The risk or severity of methemoglobinemia can be increased when Vinblastine is combined with Etidocaine. |
| Medroxyprogesterone acetate | The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Etidocaine. |
| Imatinib | The risk or severity of methemoglobinemia can be increased when Imatinib is combined with Etidocaine. |
| Clofarabine | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Etidocaine. |
| Prednisone | The risk or severity of methemoglobinemia can be increased when Prednisone is combined with Etidocaine. |